01.23.2012
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting its Potential as an Immunotherapeutic Approach in Cancer

06.06.2011
VentiRx Pharmaceuticals Presents Results from Phase 1 Clinical Trial of VTX-2337, a Novel TLR8 Agonist, in Patients with Advanced Solid Tumors at American Society of Clinical Oncology Annual Meeting

03.21.2011
VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy & Immunology Annual Meeting

10.08.2010
VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis - Establishes Proof of Concept for First In Class TLR8 Agonist in Allergy

10.04.2010
VentiRx Pharmaceuticals’ Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology

09.15.2010
FierceBiotech Names VentiRx Pharmaceuticals as One of the ‘Fierce 15’ Biotech Companies of 2010 - VentiRx is on the Leading Edge of Biotech

01.12.2010
VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing - Funds used for clinical development of the first selective TLR8 agonists

04.16.2009
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis - First Selective TLR8 Agonist to Advance for Treatment of Allergy

12.04.2008
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology - First Selective TLR8 Agonist to Advance to Clinical Trials

05.23.2008
VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors

04.16.2007
VentiRx Pharmaceuticals Appoints Kent Snyder to Board of Directors

03.13.2007
Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement

03.06.2007
VentiRx Pharmaceuticals Announces $28.9 Million Financing